Bibliography
- Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol 2013;64:21-47
- Dos Santos RG, Hallak JE, Leite JP, et al. Phytocannabinoids and epilepsy. J Clin Pharm Ther 2015;40(2):135-43
- Blair RE, Deshpande LS, Delorenzo RJ. Endocannabinoids and epilepsy. In: Fattore L, editors. Cannabinoids in neurologic and mental disease. 1st edition. Academic Press, Waltham, MA, USA; 2015:125-72
- Gloss D, Vickrey B. Cannabinoids for epilepsy. Cochrane Database Syst Rev 2014;3:CD009270
- Gross DW, Hamm J, Ashworth NL, Quigley D. Marijuana use and epilepsy: prevalence in patients of a tertiary care epilepsy center. Neurology 2004;62(11):2095-7
- Swift W, Wong A, Li KM, et al. Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PLoS ONE 2013;8(7):e70052
- Wade DT, Makela PM, House H, et al. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 2006;12(5):639-45
- Hegde M, Santos-Sanchez C, Hess CP, et al. Seizure exacerbation in two patients with focal epilepsy following marijuana cessation. Epilepsy Behav 2012;25(4):563-6
- Wilkinson ST, Radhakrishnan R, D’Souza DC. Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep 2014;1(2):115-28
- Kuepper R, van Os J, Lieb R, et al. Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study. BMJ 2011;342:d738
- Stone JM, Fisher HL, Major B, et al. Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation. Psychol Med 2014;44(3):499-506
- Bui QM, Simpson S, Nordstrom K. Psychiatric and medical management of marijuana intoxication in the emergency department. West J Emerg Med 2015;16(3):414-17
- Turu G, Hunyady L. Signal transduction of the CB1 cannabinoid receptor. J Mol Endocrinol 2010;44(2):75-85
- Braakman HM, van Oostenbrugge RJ, van Kranen-Mastenbroek VH, de Krom MC. Rimonabant induces partial seizures in a patient with a history of generalized epilepsy. Epilepsia 2009;50(9):2171-2
- Blair RE, Deshpande LS, Sombati S, et al. Prolonged exposure to WIN55,212-2 causes downregulation of the CB1 receptor and the development of tolerance to its anticonvulsant effects in the hippocampal neuronal culture model of acquired epilepsy. Neuropharmacology 2009;57(3):208-18
- Bialer M, Johannessen SI, Levy RH, et al. Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII). Epilepsy Res 2015;111:85-141
- Maa E, Figi P. The case for medical marijuana in epilepsy. Epilepsia 2014;55(6):783-6
- Porter BE, Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 2013;29(3):574-7
- Press CA, Knupp KG, Chapman KE. Parental reporting of response to oral cannabis extracts for treatment of refractory epilepsy. Epilepsy Behav 2015;45:49-52
- Cilio MR, Thiele EA, Devinsky O. The case for assessing cannabidiol in epilepsy. Epilepsia 2014;55(6):787-90
- Devinsky O, Sullivan J, Friedman D, et al. Epidiolex (cannabidiol) in treatment-resistant epilepsy. AAN 67th Annual Meeting Abstract American Academy of Neurology. Washington, DC; 2015
- Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015. [Epub ahead of print]